NCT02333162 2026-03-04
Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients With Relapsed Hematologic Cancers Undergoing a Second Donor Stem Cell Transplant
University of Chicago
Phase 1 Recruiting
Clinical Trials
5 trialsNCT07359859 2026-02-17
A Study of Ruxolitinib for Preventing Graft-Versus-Host Disease in People With a Hematologic Malignancy Who Will Receive a Stem Cell Transplant
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT04177004 2025-12-15
Human Lysozyme Goat Milk for the Prevention of Graft Versus Host Disease in Patients With Blood Cancer Undergoing a Donor Stem Cell Transplant
City of Hope Medical Center
Phase 1 Recruiting
NCT06807606 2025-12-04
Optimized Cord Blood Transplantation for the Treatment of Patients With High-risk Hematologic Malignancies Who Have Relapsed After First Allogeneic Stem Cell Transplantation
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT03670966 2025-10-16
211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome
Fred Hutchinson Cancer Center
Phase 1/2 Recruiting